Magnesium for Osteoporosis

Magnesium is often sold for bone health, but the evidence that supplements help osteoporosis is thin. Meta-analyses of observational studies find a small positive link between magnesium intake and hip bone mineral density (BMD) (Groenendijk 2022; Farsinejad-Marj 2016), and low blood magnesium is linked with more fractures (Dominguez 2023). No randomised trial has tested whether magnesium supplements prevent fractures.

The supplement studies in women with osteoporosis are a 2-year open trial of 31 women compared with women who declined treatment (Stendig-Lindberg 1993), a 30-day study of bone markers in 10 women (Aydin 2010) and a pilot that found no effect on pain (Pickering 2026). NIH's Office of Dietary Supplements concludes that more research is needed to know whether magnesium supplements can help prevent or manage osteoporosis (NIH ODS).

Bone health depends on both minerals and vitamin D. See magnesium with vitamin D for how they work together.

An adult body holds about 25 g of magnesium, and 50-60% of it sits in bone. Magnesium is involved in bone formation and influences osteoblasts and osteoclasts (the cells that build and break down bone). It also affects parathyroid hormone and the active form of vitamin D, two major regulators of bone. Women with osteoporosis have been found to have lower serum magnesium than women with osteopenia or normal bone density (NIH ODS).

Short studies show what extra magnesium does to these signals. In 10 postmenopausal women with osteoporosis, 30 days of magnesium citrate lowered parathyroid hormone and a urinary marker of bone breakdown (Aydin 2010). In 12 healthy young men, 30 days of magnesium lowered parathyroid hormone and markers of both bone formation and breakdown (Dimai 1998). Many osteoporosis medicines work by decreasing bone breakdown, so this is a plausible direction, but it is not proof of benefit (LeBoff 2022).

A shift in bone markers over a month is not stronger bone. None of these marker studies measured bone density or fractures, and two placebo-controlled trials found no change in bone turnover markers at all: one in 26 young women given 10 mmol of magnesium a day for 28 days (Doyle 1999), and a 12-week, three-arm trial in 78 adults with overweight or obesity, in which vitamin D plus 360 mg of magnesium glycinate did not change bone turnover markers compared with placebo (Dall 2023).

Blood tests don't settle it either. Most magnesium is inside cells or in bone, so serum magnesium correlates poorly with the body's total stores, and no single test is considered satisfactory (NIH ODS).

There is no proven dose of magnesium for osteoporosis. The practical target is the recommended dietary allowance (RDA): 320 mg a day for women and 420 mg a day for men over 30, counting food, drinks and supplements. In US survey data, 48% of Americans got less magnesium from food and drinks than the estimated average requirement (NIH ODS).

The tolerable upper intake level for magnesium from supplements and medicines is 350 mg a day for adults and lower for children: 65 mg at ages 1-3, 110 mg at 4-8 and 350 mg from age 9. It does not include magnesium in food (NIH ODS). The small bone studies stayed near that: 300 mg of elemental magnesium a day as oxide in girls (Carpenter 2006) and 1,830 mg of magnesium citrate a day in women with osteoporosis, which NIH ODS lists as 290 mg of elemental magnesium (Aydin 2010; NIH ODS). Labels state elemental magnesium. Citrate, chloride, lactate and aspartate are absorbed more completely than oxide and sulfate (NIH ODS).

The steadiest signal is observational. A 2022 systematic review of 12 observational studies in adults aged 60 and over pooled four of them and found higher magnesium intake was associated with higher hip BMD (pooled beta 0.03; 95% CI 0.01-0.06); there was too little research to assess other sites or fractures (Groenendijk 2022). An earlier meta-analysis of 12 studies found only marginal correlations with femoral neck BMD (r 0.14) and none with the lumbar spine (Farsinejad-Marj 2016).

In the Women's Health Initiative, among 4,778 postmenopausal women with baseline bone scans, those taking in more than 422.5 mg a day had 3% higher hip BMD than those under 206.5 mg (P<0.001). Yet across all 73,684 women, hip and total fractures did not differ by intake, and wrist and lower-arm fractures were more common at the highest intakes, possibly because those women were more active and fell more (Orchard 2014).

Fracture data conflict. Across studies, high magnesium intake was not associated with hip fracture (summary effect 1.92; 95% CI 0.81-4.55) or total fractures (Farsinejad-Marj 2016). In 3,765 American adults followed for 8 years, the highest intake quintile had fewer self-reported fractures than the lowest (women HR 0.38; 95% CI 0.17-0.82; men HR 0.47, borderline at P=0.05) (Veronese 2017). In the UK EPIC-Norfolk cohort, no link survived correction for multiple testing (Hayhoe 2015).

Blood levels show a clearer pattern. A meta-analysis of four studies with 119,755 people found low serum magnesium was associated with a higher risk of fractures (RR 1.58; 95% CI 1.22-2.05) (Dominguez 2023). In 2,245 Finnish men followed for a median of 25.6 years, the lowest serum magnesium quartile had a higher fracture risk (HR 1.80; 95% CI 1.10-2.94), while dietary intake showed no link (Kunutsor 2017). Low serum magnesium can reflect illness or medicines, so these studies can't show that supplements would help.

In the longest trial, 31 postmenopausal women with low bone density took magnesium hydroxide for 2 years; 71% had a 1-8% rise in trabecular bone density, while 23 untreated women lost density. The comparison group had declined treatment, the trial was open-label and not randomised, and the mean density of all treated women rose significantly at 1 year (P<0.02) but "remained unchanged" after 2 years (P>0.05) (Stendig-Lindberg 1993).

The other osteoporosis studies are short. Thirty days of magnesium citrate lowered parathyroid hormone and a urinary marker of bone breakdown, while osteocalcin rose, in 10 women compared with 10 untreated women (Aydin 2010). In a pilot of 44 women on intravenous zoledronate, adding 200 mg of magnesium a day for 3 months did not change pain, mood or sleep (Pickering 2026). Outside osteoporosis, a one-year placebo-controlled trial in girls aged 8-14 with low magnesium intake found a borderline gain in hip bone mineral content (P=0.05) with 300 mg a day (Carpenter 2006).

We found no randomised trial of magnesium that measured fractures, and no placebo-controlled trial in people with osteoporosis that measured bone density by DXA. The 2022 review's authors called for large, long-term randomised trials in older adults (Groenendijk 2022). A narrative review reported benefit in all seven supplementation studies it found, but several combined magnesium with other nutrients and doses ranged from 250 to 1,800 mg (Rondanelli 2021). The 2022 review also suggested that several bone nutrients together, including calcium, vitamin D and protein, may be needed for the best effect (Groenendijk 2022).

For comparison, calcium and vitamin D have far larger trial bases for osteoporosis, and boron, another mineral sold for bone, has even less evidence than magnesium. The Bone Health and Osteoporosis Foundation's clinician's guide lists adequate calcium and vitamin D, weight-bearing and resistance exercise, fall prevention and avoiding smoking and excess alcohol alongside antifracture medicine, which it says prevents fractures in appropriate patients (LeBoff 2022).

Magnesium from food is not a risk for healthy people because the kidneys excrete the excess. High doses from supplements or medicines often cause diarrhoea, nausea and abdominal cramping; carbonate, chloride, gluconate and oxide are the forms most often reported to cause diarrhoea (NIH ODS). In the girls' trial, magnesium oxide was safe and well tolerated at 300 mg a day (Carpenter 2006).

Very large doses, typically over 5,000 mg a day from laxatives or antacids, have caused magnesium toxicity, with low blood pressure, irregular heartbeat and, rarely, death. The risk rises with impaired kidney function or kidney failure, because the kidneys can no longer clear the excess (NIH ODS).

The interaction that matters most here is with osteoporosis treatment itself: magnesium-rich supplements or medicines can reduce absorption of oral bisphosphonates such as alendronate, so take them at least 2 hours apart (NIH ODS). Magnesium also binds tetracycline and quinolone antibiotics. The levothyroxine label lists magnesium hydroxide antacids among drugs that reduce its absorption and advises taking levothyroxine at least 4 hours apart from such drugs (FDA levothyroxine label).

Some common medicines lower magnesium: long-term proton pump inhibitors (typically more than a year) can cause low blood magnesium, and loop and thiazide diuretics increase magnesium loss in urine. Potassium-sparing diuretics do the opposite and reduce magnesium excretion (NIH ODS).